| Literature DB >> 27818255 |
Krishna Radhakrishnan1, Nirmal Sonali2, Miguel Moreno2, Jayabalan Nirmal2, Alexandra A Fernandez2, Subbu Venkatraman2, Rupesh Agrawal3.
Abstract
Utilization of the full clinical potential of many novel therapeutic proteins designed for diseases affecting the posterior segment of the eye has often been limited because of their inherent instability and the difficulty in overcoming various ocular barriers. Intravitreal injection is currently the only approved mode of administration, although it is suboptimal because it is painful and has to be done every 1-2 months as a result of high protein clearance rates from the vitreous humor. In this review, we discuss the status of protein drug delivery to back of the eye in terms of novel protein drugs developed, physiological barriers encountered, strategies for carrier design to overcome these limitations, and protein stability. We focus on the most promising approaches as well as on current shortcomings.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27818255 DOI： 10.1016/j.drudis.2016.10.015
Source DB: PubMed Journal: Drug Discov Today ISSN： 1359-6446 Impact factor: 7.851